Pharmacovigilance Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025

Description

The global pharmacovigilance market is projected to grow from $8,340.1 million in 2024 to $18,026.7 million by 2030, reflecting a compound annual growth rate (CAGR) of 13.9% during the forecast period.

This growth is driven by the increasing incidence of adverse drug reactions (ADRs) and a heightened emphasis on drug safety and efficacy. The rising prevalence of chronic diseases necessitates the development of new pharmaceuticals, further underscoring the importance of robust pharmacovigilance systems to monitor and manage potential drug-related risks.

Key Insights

The Phase IV (post-marketing) segment holds a significant share in the pharmacovigilance market, as continuous monitoring of drug safety after market approval is crucial for detecting rare or long-term adverse effects.

Pharmaceutical companies are the largest end-users of pharmacovigilance services, investing heavily in monitoring the safety profiles of their products to comply with stringent regulatory requirements and maintain public trust.

The spontaneous reporting segment is expected to witness substantial growth, driven by the increasing adoption of this method for its efficiency in detecting new, rare, and serious ADRs.

North America leads the pharmacovigilance market, attributed to advanced healthcare infrastructure, a high incidence of chronic diseases, and stringent regulatory policies enforcing drug safety monitoring.

The Asia-Pacific region is anticipated to experience the fastest growth during the forecast period, propelled by increasing clinical trial activities, rising healthcare expenditure, and growing awareness of drug safety among healthcare professionals and patients.

The integration of artificial intelligence (AI) and machine learning (ML) technologies in pharmacovigilance processes is enhancing the efficiency and accuracy of ADR detection, analysis, and prediction, driving market growth.

The outsourcing of pharmacovigilance services to contract research organizations (CROs) is becoming increasingly prevalent, allowing pharmaceutical companies to focus on core activities while ensuring comprehensive drug safety monitoring.

The growing emphasis on personalized medicine necessitates more complex pharmacovigilance techniques to monitor side effects and long-term consequences tailored to individual genetic profiles, influencing market dynamics.

Product Code: 10350

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by product lifecycle
- 1.4.2. Market size breakdown, by service provider
- 1.4.3. Market size breakdown, by service
- 1.4.4. Market size breakdown, by process flow
- 1.4.5. Market size breakdown, by therapeutic area
- 1.4.6. Market size breakdown, by end user
- 1.4.7. Market size breakdown, by region
- 1.4.8. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
5.2. Impact of COVID-19
5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes

Chapter 6. Global Market

6.1. Overview
6.2. Market Revenue, by Product Life Cycle (2019-2030)
6.3. Market Revenue, by Service Provider (2019-2030)
6.4. Market Revenue, by Service (2019-2030)
6.5. Market Revenue, by Process Flow (2019-2030)
6.6. Market Revenue, by Therapeutic Area (2019-2030)
6.7. Market Revenue, by End User (2019-2030)
6.8. Market Revenue, by Region (2019-2030)

Chapter 7. North America Market

7.1. Overview
7.2. Market Revenue, by Product Life Cycle (2019-2030)
7.3. Market Revenue, by Service Provider (2019-2030)
7.4. Market Revenue, by Service (2019-2030)
7.5. Market Revenue, by Process Flow (2019-2030)
7.6. Market Revenue, by Therapeutic Area (2019-2030)
7.7. Market Revenue, by End User (2019-2030)
7.8. Market Revenue, by Country (2019-2030)

Chapter 8. Europe Market

8.1. Overview
8.2. Market Revenue, by Product Life Cycle (2019-2030)
8.3. Market Revenue, by Service Provider (2019-2030)
8.4. Market Revenue, by Service (2019-2030)
8.5. Market Revenue, by Process Flow (2019-2030)
8.6. Market Revenue, by Therapeutic Area (2019-2030)
8.7. Market Revenue, by End User (2019-2030)
8.8. Market Revenue, by Country (2019-2030)

Chapter 9. APAC Market

9.1. Overview
9.2. Market Revenue, by Product Life Cycle (2019-2030)
9.3. Market Revenue, by Service Provider (2019-2030)
9.4. Market Revenue, by Service (2019-2030)
9.5. Market Revenue, by Process Flow (2019-2030)
9.6. Market Revenue, by Therapeutic Area (2019-2030)
9.7. Market Revenue, by End User (2019-2030)
9.8. Market Revenue, by Country (2019-2030)

Chapter 10. LATAM Market

10.1. Overview
10.2. Market Revenue, by Product Life Cycle (2019-2030)
10.3. Market Revenue, by Service Provider (2019-2030)
10.4. Market Revenue, by Service (2019-2030)
10.5. Market Revenue, by Process Flow (2019-2030)
10.6. Market Revenue, by Therapeutic Area (2019-2030)
10.7. Market Revenue, by End User (2019-2030)
10.8. Market Revenue, by Country (2019-2030)

Chapter 11. MEA Market

11.1. Overview
11.2. Market Revenue, by Product Life Cycle (2019-2030)
11.3. Market Revenue, by Service Provider (2019-2030)
11.4. Market Revenue, by Service (2019-2030)
11.5. Market Revenue, by Process Flow (2019-2030)
11.6. Market Revenue, by Therapeutic Area (2019-2030)
11.7. Market Revenue, by End User (2019-2030)
11.8. Market Revenue, by Country (2019-2030)

Chapter 12. U.S. Market

12.1. Overview
12.2. Market Revenue, by Product Life Cycle (2019-2030)
12.3. Market Revenue, by Service Provider (2019-2030)
12.4. Market Revenue, by Service (2019-2030)
12.5. Market Revenue, by Process Flow (2019-2030)
12.6. Market Revenue, by Therapeutic Area (2019-2030)
12.7. Market Revenue, by End User (2019-2030)

Chapter 13. Canada Market

13.1. Overview
13.2. Market Revenue, by Product Life Cycle (2019-2030)
13.3. Market Revenue, by Service Provider (2019-2030)
13.4. Market Revenue, by Service (2019-2030)
13.5. Market Revenue, by Process Flow (2019-2030)
13.6. Market Revenue, by Therapeutic Area (2019-2030)
13.7. Market Revenue, by End User (2019-2030)

Chapter 14. Germany Market

14.1. Overview
14.2. Market Revenue, by Product Life Cycle (2019-2030)
14.3. Market Revenue, by Service Provider (2019-2030)
14.4. Market Revenue, by Service (2019-2030)
14.5. Market Revenue, by Process Flow (2019-2030)
14.6. Market Revenue, by Therapeutic Area (2019-2030)
14.7. Market Revenue, by End User (2019-2030)

Chapter 15. France Market

15.1. Overview
15.2. Market Revenue, by Product Life Cycle (2019-2030)
15.3. Market Revenue, by Service Provider (2019-2030)
15.4. Market Revenue, by Service (2019-2030)
15.5. Market Revenue, by Process Flow (2019-2030)
15.6. Market Revenue, by Therapeutic Area (2019-2030)
15.7. Market Revenue, by End User (2019-2030)

Chapter 16. U.K. Market

16.1. Overview
16.2. Market Revenue, by Product Life Cycle (2019-2030)
16.3. Market Revenue, by Service Provider (2019-2030)
16.4. Market Revenue, by Service (2019-2030)
16.5. Market Revenue, by Process Flow (2019-2030)
16.6. Market Revenue, by Therapeutic Area (2019-2030)
16.7. Market Revenue, by End User (2019-2030)

Chapter 17. Italy Market

17.1. Overview
17.2. Market Revenue, by Product Life Cycle (2019-2030)
17.3. Market Revenue, by Service Provider (2019-2030)
17.4. Market Revenue, by Service (2019-2030)
17.5. Market Revenue, by Process Flow (2019-2030)
17.6. Market Revenue, by Therapeutic Area (2019-2030)
17.7. Market Revenue, by End User (2019-2030)

Chapter 18. Spain Market

18.1. Overview
18.2. Market Revenue, by Product Life Cycle (2019-2030)
18.3. Market Revenue, by Service Provider (2019-2030)
18.4. Market Revenue, by Service (2019-2030)
18.5. Market Revenue, by Process Flow (2019-2030)
18.6. Market Revenue, by Therapeutic Area (2019-2030)
18.7. Market Revenue, by End User (2019-2030)

Chapter 19. Japan Market

19.1. Overview
19.2. Market Revenue, by Product Life Cycle (2019-2030)
19.3. Market Revenue, by Service Provider (2019-2030)
19.4. Market Revenue, by Service (2019-2030)
19.5. Market Revenue, by Process Flow (2019-2030)
19.6. Market Revenue, by Therapeutic Area (2019-2030)
19.7. Market Revenue, by End User (2019-2030)

Chapter 20. China Market

20.1. Overview
20.2. Market Revenue, by Product Life Cycle (2019-2030)
20.3. Market Revenue, by Service Provider (2019-2030)
20.4. Market Revenue, by Service (2019-2030)
20.5. Market Revenue, by Process Flow (2019-2030)
20.6. Market Revenue, by Therapeutic Area (2019-2030)
20.7. Market Revenue, by End User (2019-2030)

Chapter 21. India Market

21.1. Overview
21.2. Market Revenue, by Product Life Cycle (2019-2030)
21.3. Market Revenue, by Service Provider (2019-2030)
21.4. Market Revenue, by Service (2019-2030)
21.5. Market Revenue, by Process Flow (2019-2030)
21.6. Market Revenue, by Therapeutic Area (2019-2030)
21.7. Market Revenue, by End User (2019-2030)

Chapter 22. Australia Market

22.1. Overview
22.2. Market Revenue, by Product Life Cycle (2019-2030)
22.3. Market Revenue, by Service Provider (2019-2030)
22.4. Market Revenue, by Service (2019-2030)
22.5. Market Revenue, by Process Flow (2019-2030)
22.6. Market Revenue, by Therapeutic Area (2019-2030)
22.7. Market Revenue, by End User (2019-2030)

Chapter 23. South Korea Market

23.1. Overview
23.2. Market Revenue, by Product Life Cycle (2019-2030)
23.3. Market Revenue, by Service Provider (2019-2030)
23.4. Market Revenue, by Service (2019-2030)
23.5. Market Revenue, by Process Flow (2019-2030)
23.6. Market Revenue, by Therapeutic Area (2019-2030)
23.7. Market Revenue, by End User (2019-2030)

Chapter 24. Brazil Market

24.1. Overview
24.2. Market Revenue, by Product Life Cycle (2019-2030)
24.3. Market Revenue, by Service Provider (2019-2030)
24.4. Market Revenue, by Service (2019-2030)
24.5. Market Revenue, by Process Flow (2019-2030)
24.6. Market Revenue, by Therapeutic Area (2019-2030)
24.7. Market Revenue, by End User (2019-2030)

Chapter 25. Mexico Market

25.1. Overview
25.2. Market Revenue, by Product Life Cycle (2019-2030)
25.3. Market Revenue, by Service Provider (2019-2030)
25.4. Market Revenue, by Service (2019-2030)
25.5. Market Revenue, by Process Flow (2019-2030)
25.6. Market Revenue, by Therapeutic Area (2019-2030)
25.7. Market Revenue, by End User (2019-2030)

Chapter 26. Saudi Arabia Market

26.1. Overview
26.2. Market Revenue, by Product Life Cycle (2019-2030)
26.3. Market Revenue, by Service Provider (2019-2030)
26.4. Market Revenue, by Service (2019-2030)
26.5. Market Revenue, by Process Flow (2019-2030)
26.6. Market Revenue, by Therapeutic Area (2019-2030)
26.7. Market Revenue, by End User (2019-2030)

Chapter 27. South Africa Market

27.1. Overview
27.2. Market Revenue, by Product Life Cycle (2019-2030)
27.3. Market Revenue, by Service Provider (2019-2030)
27.4. Market Revenue, by Service (2019-2030)
27.5. Market Revenue, by Process Flow (2019-2030)
27.6. Market Revenue, by Therapeutic Area (2019-2030)
27.7. Market Revenue, by End User (2019-2030)

Chapter 28. U.A.E. Market

28.1. Overview
28.2. Market Revenue, by Product Life Cycle (2019-2030)
28.3. Market Revenue, by Service Provider (2019-2030)
28.4. Market Revenue, by Service (2019-2030)
28.5. Market Revenue, by Process Flow (2019-2030)
28.6. Market Revenue, by Therapeutic Area (2019-2030)
28.7. Market Revenue, by End User (2019-2030)

Chapter 29. Competitive Landscape

29.1. List of Market Players and their Offerings
29.2. Competitive Benchmarking of Key Players
29.3. Product Benchmarking of Key Players
29.4. Recent Strategic Developments

Chapter 30. Company Profiles

30.1. Accenture plc
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
30.2. Bristol-Myers Squibb Company
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
30.3. Cognizant Technology Solutions Corporation
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
30.4. GlaxoSmithKline plc
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
30.5. ICON plc
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
30.6. Novartis AG
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
30.7. F. Hoffmann-La Roche Ltd.
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
30.8. Pfizer Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
30.9. Wipro Limited
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary

Chapter 31. Appendix

31.1. Abbreviations
31.2. Sources and References
31.3. Related Reports

Pharmacovigilance Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)